van Es-Johansson An 4

What Happened

• An van Es‑Johansson, a director of Plus Therapeutics (PSTV), was granted two equity awards on 2026-05-14, each for 3,686 derivative units, for a total of 7,372 units. Both awards were reported at $0.00 per unit (no cash paid at grant). These transactions are recorded as awards/grants (Form 4 code A), not open‑market purchases or sales.

Key Details

• Transaction date: 2026-05-14; Form 4 filed: 2026-05-18 (filed within the required two business days).
• Reported price: $0.00 per unit; total reported cash value at grant: $0.
• Shares owned after transaction: Not disclosed in the provided report.
• Footnotes of note:
  • F1: One award appears to be Restricted Stock Units (RSUs); each RSU converts to one share upon vesting. Those RSUs vest ratably over four quarters, with the first 1/4 vesting on July 1, 2026 and the remainder vesting quarterly thereafter.
  • F2: The other award appears to be an option‑style grant that vests monthly over 12 months in equal increments, and vests in full at the Issuer’s 2027 Annual Stockholder Meeting, subject to continued service.
• Filing timeliness: Timely (filed within two business days of the reported transaction).

Context

• These are derivative awards, not immediate stock purchases or sales. RSUs represent a contingent right to receive shares only as they vest; the option‑style award vests over time and may require exercise to convert to shares depending on its terms. Such grants are routine compensation for directors and do not by themselves indicate buying or selling of existing shares.